Table 6 Clinical results of sotorasib therapy in advanced cancer with KRAS-G12C
From: Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
| Â | Hong et al., 2020 (n = 129) [177] | Skoulidis et al., 2021 (n = 126) [178] |
|---|---|---|
Characteristics | ||
Median age (range, year) | 62 (33–83) | 63.5 (37–80) |
NSCLC (n) | 59 | 126 |
CRC (n) | 42 | 0 |
Other solid cancer (n) | 28 | 0 |
Treatment | Sotorasib (orally 180-960 mg/kg, once daily) | Sotorasib (orally 960 mg/kg, once daily) |
Efficacy | ||
Objective response (%) | NSCLC: 32.2; CRC: 7.1; Other: 14.3 | 37.1 |
Disease control (%) | NSCLC: 88.1; CRC: 73.8; Other: 75.0 | 80.6 |
Complete response (%) | NSCLC: 0; CRC: 0; Other: 0 | 3.2 |
Partial response (%) | NSCLC: 32.2; CRC: 7.1; Other: 14.3 | 33.9 |
Stable disease (%) | NSCLC: 55.9; CRC: 66.7; Other: 60.7 | 43.5 |
Progressive disease (%) | NSCLC: 8.5; CRC: 23.8; Other: 14.3 | 16.1 |
Could not be evaluated (%) | NSCLC: 1.7; CRC: 2.4; Other: 7.1 | 1.6 |
Adverse events | ||
Any grade (%) | 96.9 | 99.2 |
Serious (%) | 45.0 | 45.3 |
Resulting in discontinuation of treatment (%) | 7.0 | 7.1 |